The Lancet Regional Health - Europe, Journal Year: 2025, Volume and Issue: 52, P. 101294 - 101294
Published: April 9, 2025
Language: Английский
Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)
Published: Sept. 6, 2024
Language: Английский
Citations
38
Cell Death and Disease, Journal Year: 2025, Volume and Issue: 16(1)
Published: Feb. 7, 2025
Abstract Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, with limited treatment options in advanced stages. Immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting PD1/PD-L1, has emerged as promising therapeutic approach. However, significant proportion patients exhibit primary or acquired resistance, limiting the overall efficacy immunotherapy. This review provides comprehensive analysis mechanisms underlying immunotherapy resistance GC, including role tumor microenvironment, dynamic PD-L1 expression, compensatory activation other checkpoints, and genomic instability. Furthermore, explores GC-specific factors such molecular subtypes, unique evasion mechanisms, impact Helicobacter pylori infection. We also discuss emerging strategies to overcome combination therapies, novel immunotherapeutic approaches, personalized based on genomics microenvironment. By highlighting these key areas, this aims inform future research directions clinical practice, ultimately improving outcomes for GC undergoing
Language: Английский
Citations
2
Advanced Materials, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 7, 2025
Abstract The cGAS‐STING pathway is pivotal in initiating antitumor immunity. However, tumor metabolism, particularly glycolysis, negatively regulates the activation of pathway. Herein, Mn galvanic cells (MnG) are prepared via liquid‐phase exfoliation and situ replacement to modulate thereby enhancing for bidirectional synergistic H 2 ‐immunotherapy. obtained MnG can be etched by water, enabling efficient sustained generation gas 2+ . not only activated amplified through release but also regulated glucose metabolism inhibit expression three prime repair exonuclease (TREX2), synergistically injection into tumors resulted a robust immune response, providing favorable support therapy. Consequently, combination with checkpoint blockade therapy significant suppression both primary distant tumors. Furthermore, MnG‐lipiodol dispersion exhibited remarkable efficacy transarterial embolization (TAE)‐gas‐immunotherapy rabbit orthotopic liver model. present study underscores significance employing metal cell strategy enhanced immunotherapy, offering novel approach rational design bioactive materials augment immunotherapeutic effectiveness.
Language: Английский
Citations
1
The Lancet. Gastroenterology & hepatology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Language: Английский
Citations
1
Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 26, 2024
Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality.HCC due to chronic hepatitis B virus (HBV) or C (HCV) infection has decreased universal vaccination for HBV and effective antiviral therapy both HCV, but HCC related metabolic dysfunction associated steatotic liver disease (MASLD) alcohol-associated (ALD) increasing.Biannual ultrasonography serum α-fetoprotein are primary surveillance tools early detection among high-risk patients (e.g., cirrhosis, HBV).Alternative such blood-based biomarker panels abbreviated MRIs being investigated.Multiphasic CT MRI standard diagnosis, histological confirmation should be considered, especially when inconclusive findings seen on cross-sectional imaging.Staging treatment decisions complex made in multidisciplinary settings, incorporating multiple factors including tumor degree dysfunction, patient performance status, available expertise, preferences.Early-stage best treated with curative options resection, ablation, transplantation.For intermediatestage disease, locoregional therapies primarily recommended although systemic may preferred large intrahepatic burden.In advanced-stage immune checkpoint inhibitor (ICI)-based regimen.In this review article, we discuss recent epidemiology, risk factors, care continuum encompassing surveillance, staging, treatments.
Language: Английский
Citations
5
International Immunopharmacology, Journal Year: 2025, Volume and Issue: 147, P. 114006 - 114006
Published: Jan. 9, 2025
Language: Английский
Citations
0
Journal of Hepatocellular Carcinoma, Journal Year: 2025, Volume and Issue: Volume 12, P. 29 - 41
Published: Jan. 1, 2025
Purpose: Portal vein tumor thrombus (PVTT)–related severe symptomatic portal hypertension (SPH) leads to a poor prognosis in patients with advanced hepatocellular carcinoma (HCC). Traditional transjugular intrahepatic portosystemic shunt (TIPS) using covered plus bare stent can effectively relieve SPH, however, the segment is susceptible obstruction due PVTT invasion. This study aimed evaluate safety and efficacy of fully stent-TIPS (FCS-TIPS) for treatment PVTT-related SPH HCC patients. Patients Methods: retrospective enrolled 25 who underwent FCS-TIPS from June 2018 January 2024. The evaluated outcomes included overall survival (OS), technical success rate, reduction venous pressure gradient (PPG), patency control liver function complications. Results: rate was 100% without perioperative deaths or procedure-related adverse events. average PPG decreased by 13.4± 4.6 mmHg. symptom 96.0%. Variceal bleeding, ascites/hydrothorax, enteropathy rates were 100%, 95.0%, respectively. Liver showed mild improvement one month after TIPS. One patient (4.0%) experienced overt hepatic encephalopathy (OHE) three (12.0%) developed dysfunction during follow-up period. None shunt-induced extrahepatic metastasis. median OS 6.0 months cumulative at 3, 6, 12 80.0%, 52.0% 21.3%. Conclusion: safe effective treating serve as bridging therapy HCC. Keywords: stent, shunt, carcinoma, thrombus,
Language: Английский
Citations
0
Brachytherapy, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
0
Hepatology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 15, 2025
Background and Aims: Various conversion therapy options have become available to patients with unresectable HCC, but which is optimal for type of patient controversial. This study compared the efficacy safety TACE alone or combined immune checkpoint tyrosine kinase inhibitors. Approach Results: Data were retrospectively initially HCC who underwent consisting (n=459) inhibitors (n=343). Compared group that received alone, triple showed significantly higher rates overall survival (HR 0.43, 95%CI 0.35–0.53). In addition, was associated longer median progression-free (15.9 vs. 8.0 mo, p <0.001). These results confirmed in matched subsets from each group. However, subgroup analysis only intermediate advanced stages, not an early stage. Those had a rate hepatectomy after (36.4 23.5%, Among those therapy, complete tumor response (32.1 11.1%, it also frequency serious adverse events (35.6 27.0%, =0.009). Conclusions: Combining better than among HCC.
Language: Английский
Citations
0
Hepatology International, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 11, 2025
Language: Английский
Citations
0